LUF5764 | 820961-49-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: LUF5764
• 英文别名: N-(2,6-diphenyl-pyrimidin-4-yl)-3,3-dimethyl-butyramide；N-(2,6-Diphenylpyrimidin-4-YL)-3,3-dimethylbutanamide
• CAS: 820961-49-7
• 化学式: C₂₂H₂₃N₃O
• 分子量: 345.444
• InChiKey: HRLXAMBTUIRRBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-氯-2,6-二苯基嘧啶 在 氨 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 反应 24.0h， 生成 LUF5764
  参考文献：
  名称：

  2,4,6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A₁ Receptor Antagonists

  摘要：

  Adenosine receptor antagonists usually possess a bi- or tricyclic heteroaromatic structure at their core with varying substitution patterns to achieve selectivity and/or greater affinity. Taking into account molecular modeling results from a series of potent adenosine A(1) receptor antagonists, a pharmacophore was derived from which we show that a monocyclic core can be equally effective. To achieve a compound that may act at the GNS we propose imposing a restriction related to its polar surface area (PSA). In consequence, we have synthesized two novel series of pyrimidines, possessing good potency at the adenosine A, receptor and desirable PSA values. In particular, compound 30 (LUF 5735) displays excellent A, affinity (K-i = 4 nM) and selectivity (less than or equal to50% displacement of 1 muM concentrations of the radioligand at the other three adenosine receptors) and has a PSA value of 53 Angstrom2.

  DOI：

  10.1021/jm049448r

文献信息

• [EN] SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS<br/>[FR] PYRIMIDINES SUBSTITUEES UTILISEES COMME LIGANDS DE RECEPTEURS D'ADENOSINE
  申请人：UNIV LEIDEN

  公开号：WO2005033084A1

  公开（公告）日：2005-04-14

  The invention provides a compound of formula (I) wherein R and R' are selected from hydrogen, alkyl, alkenyl, alkynyl, or aryl; R'' and R''' are selected from hydrogen, acyl, thio-acyl, seleno-acyl, alkyl, alkenyl, alkynyl, or aryl; or a pharmaceutically acceptable salt thereof, to interact with the adenosine receptors in the beneficial treatment and/or prevention of a (dis)order arising from the said receptors. The invention further provides pharmaceutical compositions comprising said compounds. The invention also relates to the use of said compositions for treating an/or preventing a variety of diseases.

  本发明提供了一种化合物，其化学式为（I），其中R和R'选自氢、烷基、烯基、炔基或芳基；R''和R'''选自氢、酰基、硫酰基、硒酰基、烷基、烯基、炔基或芳基；或其药学上可接受的盐，用于与腺苷受体相互作用，有益于治疗和/或预防由该受体引起的（失）调节。本发明还提供包含该化合物的制药组合物。本发明还涉及使用该组合物治疗和/或预防各种疾病的方法。
• Substituted pyrimidines as ligands of adenosine receptors
  申请人：Chang Chung Wai Lisa

  公开号：US20070032510A1

  公开（公告）日：2007-02-08

  The invention provides a compound of formula (I) wherein R and R′ are selected from hydrogen, alkyl, alkenyl, alkynyl, or aryl; R″ and R′″ are selected from hydrogen, acyl, thio-acyl, seleno-acyl, alkyl, alkenyl, alkynyl, or aryl; or a pharmaceutically acceptable salt thereof, to interact with the adenosine receptors in the beneficial treatment and/or prevention of a (dis)order arising from the said receptors. The invention further provides pharmaceutical compositions comprising said compounds. The invention also relates to the use of said compositions for treating an/or preventing a variety of diseases.

  本发明提供化合物(I)的配方，其中R和R'选自氢，烷基，烯基，炔基或芳基；R"和R'"选自氢，酰基，硫酰基，硒酰基，烷基，烯基，炔基或芳基；或其药学上可接受的盐，与腺苷受体相互作用，有益于治疗和/或预防由该受体引起的疾病。本发明还提供包含该化合物的药物组合物。本发明还涉及使用该组合物治疗和/或预防各种疾病的用途。
• SUBSTITUTED PYRIMIDINES AS LIGANDS OF ADENOSINE RECEPTORS
  申请人：Universiteit Leiden

  公开号：EP1667985A1

  公开（公告）日：2006-06-14
• US7449470B2
  申请人：——

  公开号：US7449470B2

  公开（公告）日：2008-11-11
• 2,4,6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A₁ Receptor Antagonists
  作者：Lisa C. W. Chang、Ronald F. Spanjersberg、Jacobien K. von Frijtag Drabbe Künzel、Thea Mulder-Krieger、Gijs van den Hout、Margot W. Beukers、Johannes Brussee、Adriaan P. IJzerman

  DOI：10.1021/jm049448r

  日期：2004.12.1

  Adenosine receptor antagonists usually possess a bi- or tricyclic heteroaromatic structure at their core with varying substitution patterns to achieve selectivity and/or greater affinity. Taking into account molecular modeling results from a series of potent adenosine A(1) receptor antagonists, a pharmacophore was derived from which we show that a monocyclic core can be equally effective. To achieve a compound that may act at the GNS we propose imposing a restriction related to its polar surface area (PSA). In consequence, we have synthesized two novel series of pyrimidines, possessing good potency at the adenosine A, receptor and desirable PSA values. In particular, compound 30 (LUF 5735) displays excellent A, affinity (K-i = 4 nM) and selectivity (less than or equal to50% displacement of 1 muM concentrations of the radioligand at the other three adenosine receptors) and has a PSA value of 53 Angstrom2.